Aug 2026· Analytical Chemistry· Vol 98 32, pp.
23806-23818
· 0 citations· 34 references
Medicine
TL;DR
This programmable dual-aptamer amplified luminescent proximity homogeneous assay (AlphaLISA) provides a rapid, homogeneous, and highly adaptable strategy for tumor-derived sEVs analysis, offering promising potential for noninvasive cancer diagnostics.
Abstract
Small extracellular vesicles (sEVs) have emerged as promising biomarkers for liquid biopsy; however, the limited specificity of single-marker detection and the intrinsic heterogeneity of circulating sEVs hinder their reliable clinical application. Herein, we develop a programmable dual-aptamer amplified luminescent proximity homogeneous assay (AlphaLISA) for rapid and wash-free detection of tumor-derived sEVs. In this strategy, EpCAM and PD-L1 aptamers simultaneously recognize two membrane proteins on the same vesicle, enabling proximity-induced interaction between donor and acceptor beads to generate a chemiluminescent signal via singlet oxygen-mediated energy transfer. This dual-recognition design effectively improves analytical specificity by implementing a molecular "AND" logic requirement for signal generation. The proposed assay exhibits a broad linear range of 5.3 × 105 to 5.3 × 109 particles mL-1 with a limit of detection of 1.63 × 104 particles mL-1. Good analytical performance was demonstrated by recovery rates of 93.9-107.5% with relative standard deviations below 5%, indicating high accuracy and reproducibility. Notably, the assay enables signal readout within 1 min under homogeneous conditions, highlighting its operational simplicity and rapid response. Clinical applicability was evaluated using serum samples from 20 lung cancer patients and 20 healthy controls, achieving an area under the ROC curve of 0.87 (95% CI: 0.75-0.97), with a sensitivity of 95% and a specificity of 75%. Overall, this programmable dual-aptamer AlphaLISA platform provides a rapid, homogeneous, and highly adaptable strategy for tumor-derived sEVs analysis, offering promising potential for noninvasive cancer diagnostics.
Extracellular vesicles (EVs) have emerged as a prominent and rapidly evolving class of biomarkers, garnering an increasing amount of attention in recent years. The analysis of diverse EV-derived biomolecules, including proteins, mRNA, and miRNA, has driven the development of numerous innovative analytical technologies...
The LAPT-sEViso provides an efficient and practical approach for the rapid isolation and detection of sEV, providing a novel approach for the sEV-based liquid biopsy.
A novel, enzyme-free surface-enhanced Raman scattering (SERS) platform based on a "dual-hotspot amplification" strategy that enhances detection sensitivity but also provides a useful design concept for the ultrasensitive analysis of carbohydrate-derived biomarkers.
Mei-Qi Bao, Xiao-Yan Ma, Hong-Cai Liu et al.· Biosensors & bioelectronics· 0 citations
The rapid diagnosis of high-risk viral pathogens is critical for public health, yet current nucleic acid-based methods often necessitate pre-amplification steps. These processes can introduce amplification bias and hinder accurate quantification. To address these limitations, we report a Cas12a-mediated Field-Effect Tr...
Lateral flow immunoassay (LFIA) has been widely used for rapid on-site analysis because of its simplicity, portability, and low cost. However, its performance in competitive assays, particularly for small molecule toxins, remains limited, as the properties of antibodies and the reliance on single-mode signal often lead...
Jinzhi Han, Hongzhi Liang, Lin Luo et al.· Biosensors & bioelectronics· 0 citations
Simultaneous and accurate detection of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) is critical for the early diagnosis and monitoring of inflammatory diseases. However, conventional analytical methods are often cumbersome, time-consuming, and limited in the capacity for simultaneous multiplex analysis...
Yuhang Su, Qinwei Zhao, Ying Tang et al.· Analytical Chemistry· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.